Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Telix Innovations SA has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The company's current USPTO activity is limited to this single pending matter, which allows for a highly focused prosecution strategy. This structure is efficient for managing intellectual property without the overhead of a large, distributed portfolio. By concentrating on 1 pending office action, the applicant can ensure that all legal and technical arguments are tailored specifically to the requirements of the Biotechnology & Pharmaceuticals field.
JONES, DAMERON LEVEST is the busiest examiner for the portfolio, with 1 pending office action. This examiner is responsible for the total pending workload of the company. The involvement of 1 distinct art unit indicates a specific technical focus for the current filing. With 1 pending office action and 1 distinct examiner, the company's immediate patenting objectives are concentrated on the outcome of this single interaction at the USPTO. This centralized point of contact simplifies the administrative process and allows for a more direct dialogue between the applicant and the examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19216949 | RADIOLABELLING KIT AND METHOD FOR RADIOLABELLING | JONES, DAMERON LEVEST | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19216949 | RADIOLABELLING KIT AND METHOD FOR RADIOLABELLING | JONES, DAMERON LEVEST | 1618 | §112 | Final Rejection | — | Pending | May 23, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTelix Innovations SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dameron Levest Jones has the most, with 1 of Telix Innovations SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
